Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 10;143(8):821–836. doi: 10.1161/CIRCULATIONAHA.120.044581

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Type 2 myocardial infarction–like myocardial injury activates the DC population in the heart and the heart-draining lymph nodes. C57BL/6J mice were treated with 160 mg/kg isoproterenol to induce T2MI-like myocardial injury and flow cytometry was performed on a single cell preparation of the heart and mediastinal lymph nodes. A and B, Example micrographs (modified from Hasham et al³⁴) of isoproterenol-induced myocardial histopathology as assessed by hematoxylin and eosin staining for immunopathology (A) and Picrosirius red staining for fibrosis (B). C, Flow cytometry contour plots showing the gating for CD11c⁺ population among total CD45⁺ and corresponding quantification of cells/mg tissue (heart) or percent of total CD45⁺ cells (lymph node). D, Representative contour plots of CD11b and MHC-II staining in the CD11c⁺ population of hearts and lymph nodes of isoproterenol-treated versus control mice and corresponding quantification of CD11c⁺MHC-II⁺ cells/mg tissue (heart) or as percent of total CD11c⁺ cells (lymph node). E, Composition of the CD11c⁺ cell population in heart and lymph nodes based on CD11b and MHC-II expression. F, Representative contour blots of CD11b and XCR1 staining within the CD11c⁺ population of hearts and lymph nodes of isoproterenol-treated versus control mice and corresponding quantification of CD11b⁻XCR1⁺ cells/mg tissue (heart) or as percent of total CD11c⁺ cells (lymph node). G, Composition of the CD11c⁺ cell population in heart and lymph nodes based on CD11b and XCR1 expression. H, Levels of MHC-II expression (MFI) in CD11b⁻XCR1⁺ cDC1 cells in heart and lymph node and corresponding representative contour blots. Symbols represent individual mice. Error bars show mean±SEM; *P<0.05; **P<0.001; ***P<0.0001; ****P<0.00001 (1-way ANOVA with Dunnett multiple comparisons post hoc test comparing each time point to baseline, multiplicity-adjusted P values). cDC1, classical dendritic cell 1; DC, dendritic cells; MFI, mean fluorescence intensity; and MHC, major histocompatibility complex.